SAMe,
does it really help with Improvement of osteoarthritis pain and function?
research showsPlacebo-controlled evidence for SAMe in osteoarthritis was borderline null for pain, with an SMD of -0.17 (95% CI -0.34 to 0.01), and null for function, with an SMD of 0.02. No difference from celecoxib or nabumetone in active-comparator trials does not establish noninferiority because the trials lacked a prespecified noninferiority margin and did not exclude a placebo effect. Old, low-quality, small studies conflict, supporting C.
ads claimClaims of cartilage regeneration, a natural anti-inflammatory painkiller, or NSAID substitution exceed evidence that mainly concerns short-term pain and function. Cartilage preservation, delayed surgery, and long-term disease modification are unproven.
Useful facts when choosing a product
- Enteric-coated 400 mg products are sold online in Korea, but this is not approval for treating osteoarthritis.
- Osteoarthritis trials commonly used 1,200 mg/day orally.
- Salt form, enteric coating, and storage stability vary among products.
- Gastrointestinal discomfort, insomnia or anxiety, possible mania, and serotonergic co-medication are safety concerns.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.same.UNK.osteoarthritis-pain-and-function.improve.MULTIUnknown > SAMe > Unknown > osteoarthritis pain and function > Improvement claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The 2009 Cochrane review by Rutjes pooled four placebo-controlled trials with 656 participants and reported pain SMD -0.17 (95% CI -0.34 to 0.01) and function SMD 0.02 (95% CI -0.68 to 0.71), while rating methods and reporting as poor. The 61-participant crossover trial by Najm in 2004 and the 134-participant trial by Kim in 2009 found no difference from celecoxib and nabumetone, respectively, but they lacked placebo groups and prespecified noninferiority margins and therefore were not confirmatory noninferiority trials.
Why this is classified as C (48)
Placebo-controlled pain efficacy was at the null boundary and function was null, while no difference in active-comparator trials does not prove noninferiority. Old, low-quality, small, conflicting evidence supports C with 48 points.
Counterpoint. This osteoarthritis pain-and-function axis is separate from the depression axis in verdict 204 and does not extend to cartilage regeneration.
Rejudgment record. Reassessment (cross-check reflected) — Four placebo-controlled trials with 656 participants were borderline null for pain and null for function; no difference in active-comparator trials without prespecified margins did not establish noninferiority
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement of osteoarthritis pain | C | Placebo-controlled efficacy was at the null boundary, and active-comparator trials did not confirm noninferiority |
| Improvement of osteoarthritis function | C | Placebo-controlled function was null with an SMD of 0.02 |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Soeken et al. 2002 | Meta-analysis of RCTs | 11 RCTs | Some original trials had industry links; details unclear | Pain, functional limitation, and adverse events | Pain was similar to NSAIDs and functional limitation showed a signal versus placebo. | Key |
| Rutjes et al. 2009 | Cochrane systematic review and meta-analysis | 4 placebo-controlled trials, 656 participants | Academic; original-trial funding details unclear | Pain, function, and adverse events | Neither pain nor function showed a conclusive difference, and study quality was poor. | Key limitation |
| Kim et al. 2009 | 8-week multicenter double-blind active-comparator RCT | 134 participants | Unverified | VAS and WOMAC | No pain or functional difference between SAMe and nabumetone. | Supportive |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-17).
Final verification and publication gate: Codex · Evidence date: 2026-07-17 · Corrections: none
Cite this verdict
[Chamgap] SAMe (ademetionine) x improvement of osteoarthritis pain and function — Evidence Grade C·48. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/same-osteoarthritis-pain-function/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.